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CASE REPORT  
RESOLUTION OF GESTATIONAL GIGANTOMASTIA WITH 
TERMINATION OF PREGNANCY  
Syed Sarmad Bukhari, Haris Manan*, Mah Muneer Khan*, Syed Shahmeer Raza** 
Department of Neurosurgery, Aga Khan University Hospital, Karachi, *Department of Surgery, Khyber Teaching Hospital, Peshawar, 
**Department of Surgery, Hayatabad Medical Complex, Hayatabad-Peshawar-Pakistan 
Less than 100 cases of gestational gigantomastia have been described in literature. The aetiology 
and risk factors are not well-established. Various treatments have been used with some consensus. 
We present the case of a 47-year-old female who presented to us with bilateral gigantomastia in 
her 16th week of gestation. She had massively enlarged breasts which were very painful. Relevant 
laboratory investigations were normal. An incisional biopsy done prior to, and two trucut samples 
at presentation to us, showed normal breast tissue proliferation. In the absence of adequate pain 
control, it was decided to electively terminate the pregnancy and give a trial of tamoxifen. She 
made a rapid recovery following termination without requiring the use of tamoxifen 
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INTRODUCTION 
Breast enlargement is a natural phenomenon that 
occurs during puberty and pregnancy due to interplay 
of hormones like oestrogen, progesterone, growth 
hormone, prolactin and adrenal steroids. Any 
disturbance in this balance can potentially lead to 
Gestational Gigantomastia (gravidic gigantomastia, 
mammary hyperplasia of pregnancy) or virginal 
gigantomastia (if it occurs at puberty).1 According to 
one criterion, gigantomastia can be defined as excess 
in Breast weight that exceeds 3 % of body weight.2 
Excess weight of Breast can lead to muscular 
discomfort and ulceration due to stretching of skin.3 
Breasts are of vital importance to the health of baby 
especially in a developing country. There are only 
100 cases so far reported in literature. A case study in 
2011 led the doctors to believe Gigantomastia as one 
of the possible causes of Mondor's syndrome and by 
treating Gigantomastia at an early stage could 
potentially prevent development of Mondor's 
syndrome.4  
CASE PRESENTATION  
A 47-year-old female patient presented to the surgical 
clinic with massively enlarged breasts for the past 2 
months. She was 4 months pregnant at the time of 
presentation. Both breasts had started enlarging 
insidiously without any precipitating cause and were 
exquisitely painful. Dimensions are given in table-1. 
On examination, the skin overlying the 
breasts was erythematous and painful to touch. The 
nipple was normal in appearance and there was no 
discharge. Skin was intact without any ulceration, 
except for a scar on the right indicating the previous 
biopsy site (Figure-1). Palpation of the breasts did not 
reveal any distinct masses but a diffuse enlargement 
was appreciated. There was no axillary 
lymphadenopathy. She denied any weight loss. 
Physical examination was otherwise unremarkable. 
Her medical and surgical history was unremarkable. 
She had 8 children and never had any complications 
in any of those pregnancies. 
Standard prenatal labs; CBC with 
differential; serum chemistry panel; liver function 
tests; serum calcium and albumin levels; hormone 
profile: oestrogen, progesterone, and prolactin were 
all within normal range. 
Prior to presentation she had an incisional 
biopsy done at a different centre. There was a strong 
suspicion of inflammatory breast cancer hence 
several Trucut biopsies were taken and sent for 
histopathology. The other differential considered was 
lymphoma and tuberculosis of the breast. Results 
from the earlier biopsy and trucut specimen showed 
the tissue contained chronic inflammatory cells with 
no evidence of breast neoplasm. Considering the 
presentation of the patient it was considered prudent 
to have the Trucut repeated from different sites. This 
biopsy confirmed the histopathology to be the same 
as the previous sample.  
The diagnosis of gestational gigantomastia 
was then considered. The patient was counselled 
regarding her disease and she decided to terminate 
the pregnancy before commencing tamoxifen.  A 
week following elective therapeutic abortion, her 
condition rapidly improved. The breasts returned to 
the pre-gestation size and her pain resolved. No 
further intervention was done and the patient was not 
asked to come for follow up since she lived in a 
remote area of the country. However, inquiry about 
her status was made over the telephone. 
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Table-1: Breast dimensions of patient with 
gestational gigantomastia at 16 weeks of pregnancy 
Breast dimensions Right Left 
Breast circumference 46 cm 55 cm 
Breast length from base to nipple 30 cm 33 cm 
Breast length from underarm to the tip of nipple 47 cm 50 cm 
 
 
Figure-1: Photograph showing the patient’s 
breasts at presentation. Peau d'orange appearance 
of the skin. Incision site of the incisional biopsy 
can be seen on the right breast. 
DISCUSSION  
The occurrence of gigantomastia during pregnancy 
and puberty has given support to the theory that 
hormones such as oestrogen and prolactin can be 
implicated in the pathogenesis. This also explains the 
response to bromocriptine. Increased risk in 
multiparous women is poorly understood.5 Some 
authors have suggested that increased receptor 
sensitivity in the presence of normal hormone levels 
may be one explanation. Several cases have been 
described in association with autoimmune diseases.   
The major challenge in treating this case 
was pain control in the presence of a live foetus. 
Paracetamol was tried in the maximum possible dose 
without much benefit while NSAIDs and tramadol 
were withheld to prevent possible foetal 
complications. It was difficult to ambulate the patient 
and it was uncomfortable for her to lie down in any 
position. The early gestational period coupled with 
the severe pain demanded a more rapid solution. A 
discussion with the patient and her husband ensued 
and they decided that they would terminate the 
pregnancy and the patient would be started on 
tamoxifen. 
It is recommended to have an elective 
delivery (by induction of labour if baby is at the age 
of viability) if the condition is complicated by 
haemorrhage and necrosis of the breast, but in our 
case the severe pain was the deciding factor. 
Following elective termination of the pregnancy and 
bilateral tubal ligation, the patient’s condition rapidly 
improved on the second day. It was decided to 
withhold tamoxifen. The patient’s breasts eventually 
reduced in size considerably and she was not 
followed up because of financial constraints. 
It is interesting to note that removal of the 
foetus and the placenta led to rapid resolution. We 
believe that besides other hormones, progesterone 
and human placental lactogen may have a yet 
unidentified trophic role in these cases. On the other 
hand, since some cases of gigantomastia have been 
reported in the presence of autoimmune disease, we 
do not know whether autoimmune disease could have 
triggered the gigantomastia in this case. However, 
since the patient's condition resolved on termination 
of pregnancy, and she did not have any clinical 
features suggesting autoimmune disease, this is less 
likely. 
It is recommended to follow the preliminary 
protocol described by Rezai S et al in diagnosing and 
treating these patients.6 This protocol includes the 
following steps: 
1 - Immediate workup for a patient presenting with 
unilateral or bilateral gigantomastia includes 
a- standard prenatal labs; 
b- CBC with differential; 
c- serum chemistry panel; 
d- liver function tests; 
e- serum calcium and albumin levels; 
f- hormone profile: oestrogen, progesterone, 
and prolactin. 
2 - Send the following tests for anti-dsDNA, ANA, 
RF, anti-Smith, CCP, antithyroglobulin, and anti-
TPO, in addition to ESR and CRP, to investigate 
possible concomitant autoimmune disorders. 
3 - To evaluate malignancy, perform a breast biopsy. 
Any finding suspicious of malignancy should be 
followed up with an MRI of the head and CT scan of 
the thorax, abdomen, and pelvis to detect areas of 
metastasis. 
4 - Surgical intervention is not recommended in 
uncomplicated cases of gestational gigantomastia due 
to potential foetal compromise. 
5 - Delivery via caesarean section or induction of 
labour is recommended for pregnancies complicated 
by breast necrosis, maternal sepsis, or haemorrhage. 
6 - Trial of postpartum bromocriptine (2.5 mg twice 
daily) with cessation of breastfeeding is 
recommended to possibly reduce breast size before 
surgical intervention. If bromocriptine is used during 
pregnancy, serial foetal growth monitoring is 
recommended. 
7 - Final surgical intervention with bilateral total 
mastectomy instead of reduction mammoplasty or 
simple mastectomy is recommended, especially in 
women desiring future pregnancy. There is an 
increased rate of recurrence in patients who 
underwent simple mastectomy or reduction 
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mammoplasty. Total bilateral mastectomy is the 
preferred surgical option. 
CONCLUSION  
Very few cases of gestational gigantomastia have 
been described in literature. It is important to 
understand the presentation and complete the full 
work up to avoid mistaking it for malignant 
conditions. Most cases of gigantomastia resolve 
spontaneously in the postpartum period, as was the 
case with our patient.  
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